- Published in
- The Fund project of University of South China for Prevention and Control of COVID‐19 The Scientific Research Fund Project of Hunan Provincial Health Commission The Special Fundamental Research Project of COVID‐19 Prevention and Control of Hengyang Science
- Authors of report
- Cai Yan, Minjie Hu, Rongjuan Dai
- Date of report
- Medical conditions
- Covid 19
Summary of the Main Points/Findings:
- Background and Objective: The study titled “Safety and efficacy of mesenchymal stem cells in COVID‐19 patients: A systematic review and meta-analysis” aimed to evaluate the usefulness of mesenchymal stem cells (MSCs) in treating COVID-19. It involved a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of MSC therapy in COVID-19 patients.
- Methods and Findings: Eight RCTs with a total of 464 participants were included in this analysis. The primary outcome measured was mortality, which was significantly lower in the MSC-treated group compared to the control group (RR: 0.66, 95% CI: 0.44, 0.99). Secondary outcomes such as clinical symptom improvement rate, clinical symptom improvement time, C-reactive protein (CRP) levels, and days to hospital discharge also showed significant improvements in the MSC-treated group.
- Conclusion: The study concluded that MSCs are a viable therapy option for COVID‐19 due to their safety and potential efficacy. MSC treatment was associated with reduced mortality, improved clinical symptoms, shorter hospital stays, and decreased CRP levels. However, the authors noted that further high-quality clinical studies are required to confirm these results and establish MSC therapy as a standard treatment for COVID-19.
This is a summary of independent research published elsewhere. It is not a report of Beike treatment outcomes.
